Early cancer detectionAutoantibody profilingWHO predicts 16.4M deaths from cancer globally by 2040, up from 9.6M in 2018. This is equivalent to almost a quarter of the British population every year.We need this blood test across the UK. It’s saved my life, and everyone should have it. It will save so many lives.Rebecca. Glasgow, ScotlandWe need this blood test across the UK. It’s saved my life, and everyone should have it. It will save so many lives.Rebecca. Glasgow, ScotlandCancer drug trials using biomarkers are 6.7 times more likely to be approved for use.Today, only 12% of cancer patients in the US benefit from the transformative, approved immunotherapies.I couldn't believe it when they told me I had lung cancer. I was out of hospital just a week after the operation.Wilma. Wishaw, ScotlandI couldn't believe it when they told me I had lung cancer. I was out of hospital just a week after the operation.Wilma. Wishaw, ScotlandWe understand disease through the lens of the human immune system, to enable early detection and better treatment of disease.Extra TimeEvent—10 Feb 2020Extra Time exhibition10 Feb 2020Our campaign to get approval for a nationwide lung cancer screening programme.EventLatest@OncimmuneECDTSuccessful equity placing of £9.0 millionOpen external linkTweet—25 Mar 2021Dr Annalisa Jenkins in conversation with Adam M Hill. 'Extra Time' podcast.Article—08 Mar 2021@OncimmuneECDTProfiling some of the inspiring women that work at the forefront of the autoantibodies field at Oncimmune #IWDOpen external linkTweet—25 Mar 2021@OncimmuneECDTThe ECLS trial demonstrated a 36% reduction in late-stage diagnosis of #lungcancer with EarlyCDT Lung.Open external linkTweet—18 Jan 2021@OncimmuneECDTOncimmune taking part in "£10 million research collaboration to detect lung cancer earlier"Open external linkTweet—18 Dec 2020@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020@OncimmuneECDT"Earlier diagnosis is likely to enable more patients to benefit from recent advances in surgery, pharmacological interventions, and radiotherapy." Professor Frank SullivanOpen external linkTweet—18 Dec 2020@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020@OncimmuneECDTOncimmune's collaboration with Roche and University Medical Center Utrecht demonstrates the utility of autoantibodies in methotrexate and tocilizumab treatment selection.Open external linkTweet—18 Dec 2020Diagnostics: why are they now getting the attention they deserve?Article—10 May 2020@OncimmuneECDTOncimmune and Medicines Discovery Catapult awarded funding for COVID-19 researchOpen external linkTweet—05 Jul 2020@OncimmuneECDT"We all know the prime directive in medicine to first do no harm, and now as therapies become more complicated and technologies more advanced, we may have the opportunity to predict and prevent toxicity instead of watch and react" Dr Scott Chandler, RocheOpen external linkTweet—07 Jul 2020Has this doctor revolutionised lung cancer detection?Article—02 Nov 2019EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodulesNICE Medtech Innovation Briefing on EarlyCDT LungOpen external linkPublication—17 Mar 2020@OncimmuneECDT“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."Open external linkTweet—06 Jul 2020Webinar: The utility of autoantibodies in immuno-oncologyNovel biomarkers of immunotherapy outcomes and immune-related adverse events.Event—10 Sep 2020'Extra Time' podcast. In conversation with Dr Melanie LeeArticle—02 Sep 2020Professor Chris Molloy in conversation with Adam M Hill. 'Extra Time' podcast.Article—04 Oct 2020@OncimmuneECDTEarlyCDT Lung selected for NICE Diagnostics Assessment GuidanceOpen external linkTweet—18 Dec 2020@OncimmuneECDTProfiling some of the inspiring women that work at the forefront of the autoantibodies field at Oncimmune #IWDOpen external linkTweet—25 Mar 2021@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020@OncimmuneECDTOncimmune's collaboration with Roche and University Medical Center Utrecht demonstrates the utility of autoantibodies in methotrexate and tocilizumab treatment selection.Open external linkTweet—18 Dec 2020@OncimmuneECDT"We all know the prime directive in medicine to first do no harm, and now as therapies become more complicated and technologies more advanced, we may have the opportunity to predict and prevent toxicity instead of watch and react" Dr Scott Chandler, RocheOpen external linkTweet—07 Jul 2020@OncimmuneECDT“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."Open external linkTweet—06 Jul 2020Professor Chris Molloy in conversation with Adam M Hill. 'Extra Time' podcast.Article—04 Oct 2020@OncimmuneECDTSuccessful equity placing of £9.0 millionOpen external linkTweet—25 Mar 2021@OncimmuneECDTThe ECLS trial demonstrated a 36% reduction in late-stage diagnosis of #lungcancer with EarlyCDT Lung.Open external linkTweet—18 Jan 2021@OncimmuneECDT"Earlier diagnosis is likely to enable more patients to benefit from recent advances in surgery, pharmacological interventions, and radiotherapy." Professor Frank SullivanOpen external linkTweet—18 Dec 2020Diagnostics: why are they now getting the attention they deserve?Article—10 May 2020Has this doctor revolutionised lung cancer detection?Article—02 Nov 2019Webinar: The utility of autoantibodies in immuno-oncologyNovel biomarkers of immunotherapy outcomes and immune-related adverse events.Event—10 Sep 2020@OncimmuneECDTEarlyCDT Lung selected for NICE Diagnostics Assessment GuidanceOpen external linkTweet—18 Dec 2020Dr Annalisa Jenkins in conversation with Adam M Hill. 'Extra Time' podcast.Article—08 Mar 2021@OncimmuneECDTOncimmune taking part in "£10 million research collaboration to detect lung cancer earlier"Open external linkTweet—18 Dec 2020@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020@OncimmuneECDTOncimmune and Medicines Discovery Catapult awarded funding for COVID-19 researchOpen external linkTweet—05 Jul 2020EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodulesNICE Medtech Innovation Briefing on EarlyCDT LungOpen external linkPublication—17 Mar 2020'Extra Time' podcast. In conversation with Dr Melanie LeeArticle—02 Sep 2020
